FREDERICK, MD - (NewMediaWire) - April 19, 2021 - BioElectronics Corporation (https://www.bielcorp.com/OTC PINK: BIEL) is pleased to report Q1 2021 revenue figures, the progress on three different product launches into the OTC and medical markets, ongoing efforts to expand international distribution, and finally, new initiatives into strengthening R&D/manufacturing capabilities. First quarter sales were $605,675 which is 18% higher than Q4 2020 sales, and an impressive 73% of total 2020 revenue; these percentage increases not only document the Company’s strong growth, but also serve as objective evidence of effectiveness for the Company’s strategic repositioning as an OEM manufacturer. The Q1 2021 sales figure is robust, as there is over $306,000 of deferred sales incoming from signed contracts, for products that have yet to be shipped. Looking ahead, the Company is now working with their three major channel partners, i.e., KT Health and Scott Specialties in the OTC space, and Medi-Launch in the prescription medical market, to solidify new orders after strong initial product launches that took place in Q1 2021. Kelly Whelan, President & CEO, expressed enthusiasm, “Initial OTC feedback has been very positive, as witnessed by strong consumer reviews (averaging over 4.5 out of 5 on Amazon.com and their company websites) for both the KT Recovery+ Wave™ and DonJoy®EME products. The launch into the medical channel was slowed by the pandemic but has recently accelerated as hospitals are resuming non-emergency surgical procedures.” The Company is also pushing forward on the international sales front. In addition to re-acquiring their CE mark (which allows the Company to sell in most international countries) in late 2020, it also obtained MDSAP certification in Q1 2021, which now allows for product distribution in Canada, Australia, and New Zealand. Ms. Whelan also said, “We are now exploring expanding our OTC sales into more countries in the EU using the same strategy of identifying firms with strong retail experience selling their branded products into the retail market. We hope to be able to announce the results of these conversations in the near future. In addition, through Medi-Launch, we have signed four new international distributorships contracts for our RecoveryRx line.” Mr. Richard Staelin, Chairman of the Board, commented, “We believe it is important to keep investing in one of our core capabilities, i.e., designing and manufacturing Pulsed Short Wave Therapy medical devices. With this in mind, we are in active talks to conduct new clinical trials both with our RecoveryRx product and extensions of our OTC devices. We are also working with our contract manufacturer to strengthen our manufacturing capabilities to accommodate for increased production, amid international volatility in raw material costs.” DisclosureCertain information set forth in this email contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity ...
San Clemente, CA - (NewMediaWire) - April 19, 2021 - Global WholeHealth Partners Corp. (OTC: GWHP), a multinational supplier of over 70+ FDA Approved Diagnostic Tests, attains breakthrough on rising neurological disease."This could simply be described as nothing short of a Medical Breakthrough in Alzheimer's Disease Diagnostic Testing for us," said Charles Strongo, CEO of Global WholeHealth Partners Corp. (OTC:GWHP).Global WholeHealth Partners now has the means to identify and test for Alzheimer's disease using a Micro-Well Reader or Lateral Flow Test to measure the certain brain enzymes during the data collection process used in a positive diagnosis. This was disclosed in an 8K filed March 21, 2021 which can be found by clicking here.“We believe this announcement couldn’t come at a better time for us as we are partnering with Nunzia Pharmaceutical and their products for Neurological disorders,” said Mr. Strongo The number of Americans living with Alzheimer'sis growing — and growing fast. More than 6 million Americans of all ages have Alzheimer's. An estimated 6.2 million Americans age 65 and older are living with Alzheimer'sdementia in 2021. Seventy-two percent are age 75 or older.https://www.alz.org/alzheimers-dementia/facts-figuresAlzheimer’s disease is currently ranked as the sixth leading cause of death in the United States, but recent estimatesindicate that the disorder may rank third, just behind heart diseaseand cancer, as a cause of death for older people… Common behavioral symptoms of Alzheimer’s include sleeplessness, wandering, agitation, anxiety, and aggression. . . The damage initially appears to take place in the hippocampus and the entorhinal cortex, parts of the brain essential in forming memories.https://www.nia.nih.gov/health/alzheimers-disease-fact-sheetAlzheimer’s DiseaseThere are many causes of dementia, and Alzheimer’s disease is the most common by far in the United States and many other countries. Alzheimer’s disease can be suspected clinically, and certain brain scans can almost make the diagnosis a certainty.https://www.brightfocus.org/alzheimers/article/what-dementia“Early detection for Alzheimer's disease is not only crucial for patients and their quality of life, but this data is also used by researchers to seek out commonalities, causes and hopefully cures,” commented Strongo.Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp., said, "The Company's goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like ZIKA, Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests."GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. The Company has the capacity to deliver hundreds of thousands of tests, and can ramp up to 1 million tests per day. Currently, the Company has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA.Media Contact:Name: Charles Strongo,CEO, Global WholeHealth Partners Corp.Email: Sales@gwhpcorp.comPhone for Sales: 949-324-6691www.gwhpcorp.comThis press release contains "forward-looking statements.” Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, ...
CARSON CITY, NV - (NewMediaWire) - April 19, 2021 - Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), announces that the signed letter of intent with Advanced Bio-Oil Technologies Ltd. (ABOT), based in Denver, Colorado, as announced on February 16, 2021 has been extended by mutual agreement between the parties to June 30, 2021.Pharmagreen to date has identified a number of opportunities for acquisition and further development of the assets for tissue culture starter plantlet production, extraction and product formulation. As stated in February 16, 2021 news release, Pharmagreen will provide the raw, crude Cannabiniod oils, grown by its network of local hemp farmers and the Cannabiniod product formulations will be developed as a joint venture with ABOT, Advanced Bio-Oil Technologies Ltd. The LOI extension provides Pharmagreen with the opportunity to more thoroughly investigate the large number of site prospects and to secure the necessary funding to secure the selected real estate assets.Commenting on Pharmagreen’s progress, Peter Wojcik, President and CEO, stated, “We are moving ahead as planned with our financing plans for acquisition and biotech complex development. We look forward to providing regular updates as we progress.” ABOUT Advanced Bio-Oil Technologies Ltd. (ABOT)Advanced Bio-Oil Technologies Limited (ABOT) is providing the various industries a platform to produce Bio-Oil at-will. ABOT is using biodegradable carbon molecule and innovative oil extraction methods in its process. This extraction method would be used to produce products for the bioenergy industry, the cosmetic or the pharmaceutical. This process is producing better Bio-Oils. ABOT is pleased to have collaborations with various groups in Uzbekistan, Greece, Canada and USA. ABOT’s platform for producing high-grade CBD Medical Bio-Oil will range from skincare products to specific medical targets. Our products which will contain Hemp derived CBD which will be marketed in North & South America and Europe.About Pharmagreen Biotech, Inc.Pharmagreen Biotech, Inc., is a publicly traded (OTC PINKS: PHBI) company. Pharmagreen is a company focused on the CBD hemp industry for the production and supply of starter plantlets through a proprietary tissue culture process with the opportunity to become one of the largest players globally. Pharmagreens’ mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets to CBD hemp farmers and other flora while offering full spectrum DNA testing for plant identification, live genetics preservation using tissue cultures in low temperature storage for all plant species; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American Cannabis and agriculture sectors. For further information on the company please visit www.pharmagreen.caSafe Harbor StatementThis press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer demands; inability to replace significant customers; seasonal nature of our business. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," ...
Research Highlights: Transgender and gender-diverse people have higher rates of hypertension compared to the general population. Within two to four months of starting gender-affirming hormone therapy, transgender women had a lower average systolic blood pressure, and transgender men had a higher average systolic blood pressure. Clinicians should consistently monitor blood pressure before and after starting gender-affirming hormone therapy to take hypertension prevention measures. Embargoed until 4 a.m. CT/5 a.m. ET Monday, April 19, 2021 (NewMediaWire) - April 19, 2021 - DALLAS - Gender-affirming hormone therapy (GAHT) was associated with blood pressure changes in both transgender men and women, according to new research published today in Hypertension, an American Heart Association journal. Given the higher burden of heart attack, stroke and other cardiovascular conditions among transgender men and women, blood pressure screening and monitoring are important, especially after beginning hormone therapies. Although doctors have prescribed gender-affirming hormone therapy to transgender men and women for more than 25 years, researchers and health care professionals know little about rates of hypertension and how the effects on blood pressure change over time. Previous research has shown that transgender men were almost five times as likely to report having a heart attack compared to cisgender women. Conversely, transgender women were more than two-and-a-half times more likely to have reported a heart attack than cisgender women, yet they did not have a significant increase in heart attack incidence when compared with cisgender men. However, a systematic review conducted in 2020 found most of the studies examining gender-affirming hormones and blood pressure had sample sizes that were too small to detect statistically significant differences in blood pressure. “There are many important gaps in our knowledge about the effects of hormone therapy for transgender people. This study examined the time course and magnitude of the effects of gender-affirming hormones on blood pressure,” said senior study author Michael S. Irwig, M.D., an associate professor of medicine at Harvard Medical School and director of transgender medicine at Beth Israel Deaconess Medical Center in Boston. To conduct the largest and longest observational study of its kind, the researchers followed 470 patients who began GAHT at a medical center in the Washington, D.C. area from 1/1/2007 to 6/1/2015. Participants were all at least 17 years old and non-cisgender. Of the 470 patients, 247 were transfeminine and 223 were transmasculine. About 27% of the participants were non-white, and 16% self-identified as Latinx. Researchers measured each patient’s blood pressure before beginning GAHT to establish a baseline and continued measurements at subsequent clinical visits for up to 57 months. The study found: Within two to four months of beginning hormone therapy, transgender women saw an average decrease of 4.0 mm Hg in their systolic blood pressure, but transgender men saw an average increase of 2.6 mm Hg. The prevalence of stage 2 hypertension (at least 140/90 mm Hg) dropped from 19% to 10% in the transfeminine group within two to four months of beginning hormone therapy. The use of testosterone in transgender men could lead to an increased risk for heart attack or stroke if they also have untreated high blood pressure. In addition, the results indicated that some patients experienced different blood pressure effects compared to the majority of those with the same gender identity. Some transgender women and transgender men saw blood pressure rates trend in the opposite direction of their peers. The study authors highlight this is an area that requires further research, noting individuals taking the same medication may react in different ways. The study has several limitations. Most patients were on the same formulation of intramuscular ...
Highlights: To date, no adverse cardiac events related to SARS-CoV-2 infection have been observed among more than 3,000 collegiate athletes during short-term clinical surveillance. Findings suggest safe return-to-play without cardiac testing for asymptomatic or mildly symptomatic athletes. Embargoed until 12:00 p.m. CDT / 1:00 p.m. EDT April 17, 2021 (NewMediaWire) - April 17, 2021 - DALLAS - While the lasting impact of COVID-19 on hospitalized patients in the general population is common and associated with adverse cardiac outcomes, evaluations of cardiac involvement of more than 3,000 college-aged, competitive athletes revealed no adverse cardiac events following COVID-19 infections and indicate a safe return-to-play for asymptomatic and mildly symptomatic athletes without additional cardiac testing, according to a study published today in the American Heart Association’s flagship journal Circulation. In this prospective, multicenter, observational cohort study with data collected from September 1 to December 31, 2020, from 42 colleges and universities in the U.S., researchers assessed the prevalence, clinical characteristics and outcomes of SARS-CoV-2 cardiac involvement among collegiate athletes using the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA). ORCCA is a national registry, or research database, to track COVID-19 cases and heart-related impacts in NCAA athletes to drive improvements in screening and inform our understanding of cardiac involvement in college athletes who have had COVID-19. “The very timely and largely reassuring data coming from the ORCCA registry were made possible by an amazing collaborative effort between the sports medicine and sports cardiology communities,” said Aaron L. Baggish, M.D., co-principal investigator and director of the Cardiovascular Performance Program at Massachusetts General Hospital in Boston. “It is anticipated that ORCCA will continue to shape the way we protect the health of young competitive athletes well beyond the end of the COVID-19 pandemic.” Out of more than 19,000 athletes tested for SARS-CoV-2 infection, 3,018 tested positive for COVID-19 and underwent cardiac evaluation. A total of 2,820 athletes underwent at least one element of cardiac ‘triad’ testing (12-lead electrocardiography (ECG), troponin, and/or transthoracic echocardiography(TTE)), followed by cardiac magnetic resonance (CMR) if clinically indicated; and 198 athletes underwent a primary screening CMR. Overall, the prevalence of probable or definite cardiac involvement from SARS-CoV-2 infection was 0.4%-1.5%. The diagnostic yield for probable or definite cardiac involvement was 6.7 times higher for a CMR obtained for clinical reasons (10.1%) versus a primary screening CMR (1.5%). The odds of having cardiac involvement was also 3.1 times higher in athletes with cardiopulmonary symptoms. “This was an amazing collaboration within the sports medicine and cardiology community,” said Jonathan A. Drezner, M.D., director of the UW Medicine Center for Sports Cardiology in Seattle and a co-principal investigator of the study. “Most athletes with no symptoms or mild illness from SARS-CoV-2 can return to sports safely without additional cardiac testing as long as they feel good on return to exercise and don’t have cardiopulmonary symptoms like chest pain.” The American Heart Association and the American Medical Society for Sports Medicine (AMSSM) joined forces earlier this year to accelerate a critical new research initiative studying cardiac conditions in athletes, in part to speed new insights into the impact of COVID-19 to the cardiovascular system of college athletes and safety of return to play after diagnosis. The collaborative data registry will aid research on COVID-19, and, long-term, develop a deep knowledge base on cardiac disease in athletes beyond the pandemic. The registry has been developed with participation from the NCAA and has more than 60 schools currently contributing to the registry. Schools interested in participating or learning more about the registry can send an ...
Tulsa, OK - (NewMediaWire) - April 16, 2021 - AppSwarm, Corp. (OTC: SWRM), a software development company and aggregator of mobile applications, announced the launch of http://dogelabs.io/ to develop commercial applications around the Dogecoin blockchain protocol.The Company announces the launch of DogeLabs.io, which will embark on application research, seminars, blockchain workshops, and will utilize its video conferencing capabilities to bring together global minds and developer insights around the Doge community. http://dogelabs.io/Application DevelopmentDogeLabs will work on leveraging Doge’s underlying liquidity to develop commercial applications that utilize Dogecoin blockchain for mobile and web-based products.Why Dogecoin?Doge offers high liquidity, fast transaction speed, and brand popularity, which could make it a unique protocol on which to build new commercial applications such as money transfers, micropayments, in-app purchases, and customer rewards.Developers recently released a new version of the protocol's core that promises improved synchronization speed and reduced default mempool expiry time.Developers say they've significantly improved the speed at which a DOGE node can upload blocks, by removing expensive integrity checks that were performed each time a block is sent to another node. Startup AcceleratorDogeLabs, in conjunction with TulsaLabs.io, is launching a startup accelerator that will assist in providing access to seed funding, training and mentorship to blockchain startups to help them pass successfully through the early stages of business growth.Our labs goal is to provide investments for novel ideas developers may have seeking to build commercial applications or integrate current blockchain protocols around their existing business models.Partnerships and CollaborationsTulsaLabs.io is currently seeking companies and blockchain developers who wish to explore integrating Doge protocol into new and exciting mobile and web-based application products. http://dogelabs.io/partner-with-us/The company will be announcing new members to its blockchain advisory board in the coming weeks as we embark on building a premier blockchain development consulting and research firm headquartered in Tulsa, OK.About APPSWARMAppSwarm is a technology company specializing in accelerated development and publishing of mobile apps and other software platforms for gaming and business applications and seeks to acquire symmetric business opportunities. AppSwarm partners with and assists other development firms in technology development, business management, and funding needs.For more information, follow us on www.app-swarm.com FaceBook www.facebook.com/AppSwarm Twitter https://twitter.com/AppSwarm or Instagram https://www.instagram.com/appswarm/“LEGAL”DogeLabs is strictly a research firm focused on the development of blockchain applications, and in no way is involved with the buying, selling, issuance of any cryptocurrencies, or investment advice.Forward-Looking Statements:"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements that are subject to risk and uncertainties including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk, and other risks detailed from time to time in the Company's filings with OTCMarkets.com and as required to the Securities and Exchange Commission. These risks could cause SWRM's actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.Investor and Media Contacts:AppSwarm, Corp.888-886-8583info@app-swarm.com
